Efficacy and safety of Piclidenoson in the treatment of plaque psoriasis: a systematic review and meta-analysis of randomized controlled trials
<p dir="ltr">Psoriasis, an autoimmune inflammatory disease characterized by hyperproliferation of keratinocytes, affects 0.2–4.8% of the global population. The disease manifests primarily as plaque psoriasis, causing chronic physical and psychological burdens. Although numerous treat...
Saved in:
| Main Author: | |
|---|---|
| Other Authors: | , , , , , , , |
| Published: |
2024
|
| Subjects: | |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1864513539956277248 |
|---|---|
| author | Muhammad Zain Ul Haq (22225279) |
| author2 | Saad Ashraf (22225282) Ayesha Shaukat (21296623) Laveeza Fatima (19231388) Muhammad Shahmeer Ullah Shah (22225285) Muhammad Ahsan Ansari (22225288) Muhammad Nabeel Saddique (19757076) Gharira Batool (22225291) Javed Iqbal (2121922) |
| author2_role | author author author author author author author author |
| author_facet | Muhammad Zain Ul Haq (22225279) Saad Ashraf (22225282) Ayesha Shaukat (21296623) Laveeza Fatima (19231388) Muhammad Shahmeer Ullah Shah (22225285) Muhammad Ahsan Ansari (22225288) Muhammad Nabeel Saddique (19757076) Gharira Batool (22225291) Javed Iqbal (2121922) |
| author_role | author |
| dc.creator.none.fl_str_mv | Muhammad Zain Ul Haq (22225279) Saad Ashraf (22225282) Ayesha Shaukat (21296623) Laveeza Fatima (19231388) Muhammad Shahmeer Ullah Shah (22225285) Muhammad Ahsan Ansari (22225288) Muhammad Nabeel Saddique (19757076) Gharira Batool (22225291) Javed Iqbal (2121922) |
| dc.date.none.fl_str_mv | 2024-11-16T09:00:00Z |
| dc.identifier.none.fl_str_mv | 10.1007/s00403-024-03506-y |
| dc.relation.none.fl_str_mv | https://figshare.com/articles/journal_contribution/Efficacy_and_safety_of_Piclidenoson_in_the_treatment_of_plaque_psoriasis_a_systematic_review_and_meta-analysis_of_randomized_controlled_trials/30095257 |
| dc.rights.none.fl_str_mv | CC BY 4.0 info:eu-repo/semantics/openAccess |
| dc.subject.none.fl_str_mv | Biomedical and clinical sciences Clinical sciences Pharmacology and pharmaceutical sciences Health sciences Epidemiology Piclidenoson Psoriasis Plaque psoriasis A3 adenosine receptor A3AR agonist Meta-analysis |
| dc.title.none.fl_str_mv | Efficacy and safety of Piclidenoson in the treatment of plaque psoriasis: a systematic review and meta-analysis of randomized controlled trials |
| dc.type.none.fl_str_mv | Text Journal contribution info:eu-repo/semantics/publishedVersion text contribution to journal |
| description | <p dir="ltr">Psoriasis, an autoimmune inflammatory disease characterized by hyperproliferation of keratinocytes, affects 0.2–4.8% of the global population. The disease manifests primarily as plaque psoriasis, causing chronic physical and psychological burdens. Although numerous treatments exist, there is ongoing exploration for novel therapies due to concerns about the toxicity, efficacy, and costs of current options. An A3 adenosine receptor (A3AR) agonist called Piclidenoson has been shown to reduce inflammation and could be used to treat moderate to severe psoriasis. This meta-analysis evaluates the safety and efficacy of Piclidenoson in psoriasis treatment. This meta-analysis was conducted accordance with the PRISMA guidelines and has been registered on PROSPERO (CRD42024566459). A comprehensive search on Cochrane CENTRAL, PubMed/MEDLINE, and Google Scholar was conducted up to July 2024. Included studies were randomized controlled trials (RCTs) involving Piclidenoson. Efficacy outcomes included PASI 75 and PGA 0 or 1, while safety outcomes included adverse events. Pooled outcomes were presented as odds ratio (OR) with 95% confidence intervals (CI). Statistical analysis employed the Mantel-Haenszel random-effects model, and heterogeneity was assessed using the I<sup>2</sup> and X<sup>2</sup>index. Three RCTs with 574 patients (313 Piclidenoson, 261 placebo) met the inclusion criteria. The pooled analysis showed no significant difference in achieving PASI 75 between Piclidenoson and placebo (OR: 1.62, 95% CI 0.70–3.75, <i>P</i>= 0.26, I<sup>2</sup> = 12%). However, Piclidenoson significantly improved PGA scores (OR: 2.74, 95% CI 1.22–6.16, <i>P</i>= 0.01, I²=0%). Safety assessment revealed no significant differences in adverse events, including nervous system, gastrointestinal, musculoskeletal, renal, and infections, compared to placebo. Piclidenoson demonstrates a significant improvement in PGA scores and a favorable safety profile, suggesting it could be a valuable addition to plaque-like psoriasis treatment. Further research with larger, longer-term RCTs is needed to confirm its efficacy and optimize clinical use.</p><h2>Other Information</h2><p dir="ltr">Published in: Archives of Dermatological Research<br>License: <a href="https://creativecommons.org/licenses/by/4.0" target="_blank">https://creativecommons.org/licenses/by/4.0</a><br>See article on publisher's website: <a href="https://dx.doi.org/10.1007/s00403-024-03506-y" target="_blank">https://dx.doi.org/10.1007/s00403-024-03506-y</a></p> |
| eu_rights_str_mv | openAccess |
| id | Manara2_cdfce5c0d8f5d1211f6925edb13aeedf |
| identifier_str_mv | 10.1007/s00403-024-03506-y |
| network_acronym_str | Manara2 |
| network_name_str | Manara2 |
| oai_identifier_str | oai:figshare.com:article/30095257 |
| publishDate | 2024 |
| repository.mail.fl_str_mv | |
| repository.name.fl_str_mv | |
| repository_id_str | |
| rights_invalid_str_mv | CC BY 4.0 |
| spelling | Efficacy and safety of Piclidenoson in the treatment of plaque psoriasis: a systematic review and meta-analysis of randomized controlled trialsMuhammad Zain Ul Haq (22225279)Saad Ashraf (22225282)Ayesha Shaukat (21296623)Laveeza Fatima (19231388)Muhammad Shahmeer Ullah Shah (22225285)Muhammad Ahsan Ansari (22225288)Muhammad Nabeel Saddique (19757076)Gharira Batool (22225291)Javed Iqbal (2121922)Biomedical and clinical sciencesClinical sciencesPharmacology and pharmaceutical sciencesHealth sciencesEpidemiologyPiclidenosonPsoriasisPlaque psoriasisA3 adenosine receptorA3AR agonistMeta-analysis<p dir="ltr">Psoriasis, an autoimmune inflammatory disease characterized by hyperproliferation of keratinocytes, affects 0.2–4.8% of the global population. The disease manifests primarily as plaque psoriasis, causing chronic physical and psychological burdens. Although numerous treatments exist, there is ongoing exploration for novel therapies due to concerns about the toxicity, efficacy, and costs of current options. An A3 adenosine receptor (A3AR) agonist called Piclidenoson has been shown to reduce inflammation and could be used to treat moderate to severe psoriasis. This meta-analysis evaluates the safety and efficacy of Piclidenoson in psoriasis treatment. This meta-analysis was conducted accordance with the PRISMA guidelines and has been registered on PROSPERO (CRD42024566459). A comprehensive search on Cochrane CENTRAL, PubMed/MEDLINE, and Google Scholar was conducted up to July 2024. Included studies were randomized controlled trials (RCTs) involving Piclidenoson. Efficacy outcomes included PASI 75 and PGA 0 or 1, while safety outcomes included adverse events. Pooled outcomes were presented as odds ratio (OR) with 95% confidence intervals (CI). Statistical analysis employed the Mantel-Haenszel random-effects model, and heterogeneity was assessed using the I<sup>2</sup> and X<sup>2</sup>index. Three RCTs with 574 patients (313 Piclidenoson, 261 placebo) met the inclusion criteria. The pooled analysis showed no significant difference in achieving PASI 75 between Piclidenoson and placebo (OR: 1.62, 95% CI 0.70–3.75, <i>P</i>= 0.26, I<sup>2</sup> = 12%). However, Piclidenoson significantly improved PGA scores (OR: 2.74, 95% CI 1.22–6.16, <i>P</i>= 0.01, I²=0%). Safety assessment revealed no significant differences in adverse events, including nervous system, gastrointestinal, musculoskeletal, renal, and infections, compared to placebo. Piclidenoson demonstrates a significant improvement in PGA scores and a favorable safety profile, suggesting it could be a valuable addition to plaque-like psoriasis treatment. Further research with larger, longer-term RCTs is needed to confirm its efficacy and optimize clinical use.</p><h2>Other Information</h2><p dir="ltr">Published in: Archives of Dermatological Research<br>License: <a href="https://creativecommons.org/licenses/by/4.0" target="_blank">https://creativecommons.org/licenses/by/4.0</a><br>See article on publisher's website: <a href="https://dx.doi.org/10.1007/s00403-024-03506-y" target="_blank">https://dx.doi.org/10.1007/s00403-024-03506-y</a></p>2024-11-16T09:00:00ZTextJournal contributioninfo:eu-repo/semantics/publishedVersiontextcontribution to journal10.1007/s00403-024-03506-yhttps://figshare.com/articles/journal_contribution/Efficacy_and_safety_of_Piclidenoson_in_the_treatment_of_plaque_psoriasis_a_systematic_review_and_meta-analysis_of_randomized_controlled_trials/30095257CC BY 4.0info:eu-repo/semantics/openAccessoai:figshare.com:article/300952572024-11-16T09:00:00Z |
| spellingShingle | Efficacy and safety of Piclidenoson in the treatment of plaque psoriasis: a systematic review and meta-analysis of randomized controlled trials Muhammad Zain Ul Haq (22225279) Biomedical and clinical sciences Clinical sciences Pharmacology and pharmaceutical sciences Health sciences Epidemiology Piclidenoson Psoriasis Plaque psoriasis A3 adenosine receptor A3AR agonist Meta-analysis |
| status_str | publishedVersion |
| title | Efficacy and safety of Piclidenoson in the treatment of plaque psoriasis: a systematic review and meta-analysis of randomized controlled trials |
| title_full | Efficacy and safety of Piclidenoson in the treatment of plaque psoriasis: a systematic review and meta-analysis of randomized controlled trials |
| title_fullStr | Efficacy and safety of Piclidenoson in the treatment of plaque psoriasis: a systematic review and meta-analysis of randomized controlled trials |
| title_full_unstemmed | Efficacy and safety of Piclidenoson in the treatment of plaque psoriasis: a systematic review and meta-analysis of randomized controlled trials |
| title_short | Efficacy and safety of Piclidenoson in the treatment of plaque psoriasis: a systematic review and meta-analysis of randomized controlled trials |
| title_sort | Efficacy and safety of Piclidenoson in the treatment of plaque psoriasis: a systematic review and meta-analysis of randomized controlled trials |
| topic | Biomedical and clinical sciences Clinical sciences Pharmacology and pharmaceutical sciences Health sciences Epidemiology Piclidenoson Psoriasis Plaque psoriasis A3 adenosine receptor A3AR agonist Meta-analysis |